Oleg Fedorov
PI, Group Head
- Biochemistry and Biophysics
Molecular Biophysics and Biochemistry group in CMD/TDI Oxford specialises on chemical probe discovery projects, especially in the field of Epigenetics and Ubiquitin system. Main target areas are acetyl-lysine reader domains and E3 ligases. The group supports the wide variety of screening assays developed for most of the targets. The in-depth characterization of drug candidates relies on a series of biophysical techniques established for accurate measurements of thermodynamics of and kinetic parameters of binding. The group also supports and extend the focused libraries of small molecular weight ligands for proteins of interest.
Recent publications
-
Unexpected Noncovalent Off-Target Activity of Clinical BTK Inhibitors Leads to Discovery of a Dual NUDT5/14 Antagonist
Balıkçı E. et al, (2024), Journal of Medicinal Chemistry, 67, 7245 - 7259
-
Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor.
Xiong Y. et al, (2024), Journal of medicinal chemistry, 67, 5837 - 5853
-
Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Henderson SH. et al, (2024), European journal of medicinal chemistry, 269
-
Discovery of PFI-6, a small-molecule chemical probe for the YEATS domain of MLLT1 and MLLT3.
Raux B. et al, (2024), Bioorganic & medicinal chemistry letters, 98
-
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
Boby ML. et al, (2023), Science, 382